Specify a stock or a cryptocurrency in the search bar to get a summary
Spago Nanomedical AB
SPAGOSpago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under Preclinical development stage. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden. Address: ScheelevAegen 22, Lund, Sweden, 223 63
Analytics
WallStreet Target Price
10.81 SEKP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures SPAGO
Dividend Analytics SPAGO
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History SPAGO
Stock Valuation SPAGO
Financials SPAGO
Results | 2019 | Dynamics |